GRI BIO INC (GRI) Stock News

USA - NASDAQ:GRI - US3622AW4030 - Common Stock

1.69 USD

0 (0%)

Last: 11/14/2025, 6:28:23 PM

1.68 USD

-0.01 (-0.59%)

After Hours: 11/14/2025, 6:28:23 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

GRI Latest News, Press Relases and Analysis

All

Press Releases

2 months ago - By: Benzinga - Mentions: BRTX ONCO MBX THAR ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

2 months ago - By: Benzinga - Mentions: IVA COCP ADXN ANEB ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

9 months ago - By: GRI Bio, Inc.

GRI Bio Announces Reverse Stock Split

2 months ago - By: GRI Bio, Inc.

GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

2 months ago - By: GRI Bio, Inc.

GRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

3 months ago - By: GRI Bio, Inc.

GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

4 months ago - By: GRI Bio, Inc.

GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment

4 months ago - By: GRI Bio, Inc.

GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

4 months ago - By: GRI Bio, Inc.

GRI Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

4 months ago - By: ACCESS Newswire - Mentions: AKTX AMIX CNSP NVNO ...

JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live

5 months ago - By: GRI Bio, Inc.

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

5 months ago - By: GRI Bio, Inc.

GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

6 months ago - By: GRI Bio, Inc.

GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results

6 months ago - By: GRI Bio, Inc.

GRI Bio to Participate in the Virtual Investor Closing Bell Series

6 months ago - By: GRI Bio, Inc.

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

6 months ago - By: GRI Bio, Inc.

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

6 months ago - By: GRI Bio, Inc.

GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

6 months ago - By: GRI Bio, Inc.

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

7 months ago - By: GRI Bio, Inc.

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

8 months ago - By: GRI Bio, Inc.

GRI Bio Announces Closing of $5.0 Million Public Offering

8 months ago - By: GRI Bio, Inc.

GRI Bio Announces Pricing of $5.0 Million Public Offering

8 months ago - By: GRI Bio, Inc.

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

8 months ago - By: GRI Bio, Inc.

GRI Bio Participates in a Virtual Investor CEO Connect Segment

8 months ago - By: GRI Bio, Inc.

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

8 months ago - By: GRI Bio, Inc.

GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule

9 months ago - By: GRI Bio, Inc.

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

a year ago - By: GRI Bio, Inc.

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

a year ago - By: GRI Bio, Inc.

GRI Bio to Participate in the Virtual Investor Closing Bell Series

a year ago - By: GRI Bio, Inc.

GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

a year ago - By: GRI Bio, Inc.

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis